Last reviewed · How we verify
Daily oral dose of hepcortespenlisimut-L
Daily oral dose of hepcortespenlisimut-L is a Therapeutic vaccine Biologic drug developed by Immunitor LLC. It is currently in Phase 2 development for Chronic hepatitis C infection (HCV). Also known as: V5.
Hepcortespenlisimut-L is an oral therapeutic vaccine that stimulates immune responses against hepatitis C virus (HCV) antigens to enhance viral clearance.
Hepcortespenlisimut-L is an oral therapeutic vaccine that stimulates immune responses against hepatitis C virus (HCV) antigens to enhance viral clearance. Used for Chronic hepatitis C infection (HCV).
At a glance
| Generic name | Daily oral dose of hepcortespenlisimut-L |
|---|---|
| Also known as | V5 |
| Sponsor | Immunitor LLC |
| Drug class | Therapeutic vaccine |
| Target | Hepatitis C virus antigens (multiple epitopes) |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 2 |
Mechanism of action
This drug is a therapeutic vaccine candidate designed to boost T-cell and B-cell immune responses against HCV in chronically infected patients. It combines HCV-derived peptides with an immunological adjuvant to promote cell-mediated immunity, potentially allowing patients to clear persistent HCV infection or reduce viral load. The oral formulation aims to induce mucosal and systemic immune responses.
Approved indications
- Chronic hepatitis C infection (HCV)
Common side effects
- Gastrointestinal disturbances
- Injection site or local reactions
- Mild fever or systemic symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daily oral dose of hepcortespenlisimut-L CI brief — competitive landscape report
- Daily oral dose of hepcortespenlisimut-L updates RSS · CI watch RSS
- Immunitor LLC portfolio CI
Frequently asked questions about Daily oral dose of hepcortespenlisimut-L
What is Daily oral dose of hepcortespenlisimut-L?
How does Daily oral dose of hepcortespenlisimut-L work?
What is Daily oral dose of hepcortespenlisimut-L used for?
Who makes Daily oral dose of hepcortespenlisimut-L?
Is Daily oral dose of hepcortespenlisimut-L also known as anything else?
What drug class is Daily oral dose of hepcortespenlisimut-L in?
What development phase is Daily oral dose of hepcortespenlisimut-L in?
What are the side effects of Daily oral dose of hepcortespenlisimut-L?
What does Daily oral dose of hepcortespenlisimut-L target?
Related
- Drug class: All Therapeutic vaccine drugs
- Target: All drugs targeting Hepatitis C virus antigens (multiple epitopes)
- Manufacturer: Immunitor LLC — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for Chronic hepatitis C infection (HCV)
- Also known as: V5
- Compare: Daily oral dose of hepcortespenlisimut-L vs similar drugs
- Pricing: Daily oral dose of hepcortespenlisimut-L cost, discount & access